| ONDRIŠOVÁ, Laura, Václav ŠEDA, Giorgia CHIODIN, Kryštof HLAVÁČ, Lenka KOŠŤÁLOVÁ, Daniel FILIP, Pedro FARIA ZENI, Anna PANOVSKÁ, Karla PLEVOVÁ, Šárka POSPÍŠILOVÁ, Martin ŠIMKOVIČ, Filip VRBACKÝ, Daniel LYSÁK, Stacey M. FERNANDEZ, MS. DAVIDS, Alba MAIQUES-DIAZ, Stella CHARALAMPOPOULOU, Jose I. MARTIN-SUBERO, Jennifer R. BROWN, Michael DOUBEK, Francesco FORCONI, Jiří MAYER and Marek MRÁZ. FOXO1-RICTOR AXIS induces adaptive increase in AKT activity during BCR inhibitor therapy in CLL: Implications for combination therapy. In EHA 2023 in HemaSphere (2023). 2023. ISSN 2572-9241. |
Other formats:
BibTeX
LaTeX
RIS
@proceedings{60347,
author = {Ondrišová, Laura and Šeda, Václav and Chiodin, Giorgia and Hlaváč, Kryštof and Košťálová, Lenka and Filip, Daniel and Faria Zeni, Pedro and Panovská, Anna and Plevová, Karla and Pospíšilová, Šárka and Šimkovič, Martin and Vrbacký, Filip and Lysák, Daniel and Fernandez, Stacey M. and Davids, MS. and MaiquesandDiaz, Alba and Charalampopoulou, Stella and MartinandSubero, Jose I. and Brown, Jennifer R. and Doubek, Michael and Forconi, Francesco and Mayer, Jiří and Mráz, Marek},
booktitle = {EHA 2023 in HemaSphere (2023)},
keywords = {BCR inhibitors; BTK inhibitors; CCL; BCR; FoxO1/Rictor},
language = {eng},
title = {FOXO1-RICTOR AXIS induces adaptive increase in AKT activity during BCR inhibitor therapy in CLL: Implications for combination therapy.},
url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428416/pdf/hs9-7-e8228434.pdf},
year = {2023}
}
TY - CONF
ID - 60347
AU - Ondrišová, Laura - Šeda, Václav - Chiodin, Giorgia - Hlaváč, Kryštof - Košťálová, Lenka - Filip, Daniel - Faria Zeni, Pedro - Panovská, Anna - Plevová, Karla - Pospíšilová, Šárka - Šimkovič, Martin - Vrbacký, Filip - Lysák, Daniel - Fernandez, Stacey M. - Davids, MS. - Maiques-Diaz, Alba - Charalampopoulou, Stella - Martin-Subero, Jose I. - Brown, Jennifer R. - Doubek, Michael - Forconi, Francesco - Mayer, Jiří - Mráz, Marek
PY - 2023
TI - FOXO1-RICTOR AXIS induces adaptive increase in AKT activity during BCR inhibitor therapy in CLL: Implications for combination therapy.
KW - BCR inhibitors
KW - BTK inhibitors
KW - CCL
KW - BCR
KW - FoxO1/Rictor
UR - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428416/pdf/hs9-7-e8228434.pdf
N2 - Genetic mechanisms of resistance to BCR inhibitors in CLL have been extensively described. However, it remainsunknown whether non-genetic adaptation mechanisms to BTK inhibitors might exist. We focused on the possible role of the Akt pathway in adapting to BCR inhibitors since, in mouse models, PI3K-Akt activation is the only known factor that rescues the apoptosis induced by BCR deletion in mature B cells. We aim to describe non-genetic mechanisms of adaptation to BCR inhibitor therapy. We performed transcriptome profiling (Illumina) and analyzed samples obtained from CLL patients before and during ibrutinib or idelalisib therapy and performed gene editing in MEC1 cells to reveal the functional role of FoxO1/Rictor.
ER -
ONDRIŠOVÁ, Laura, Václav ŠEDA, Giorgia CHIODIN, Kryštof HLAVÁČ, Lenka KOŠŤÁLOVÁ, Daniel FILIP, Pedro FARIA ZENI, Anna PANOVSKÁ, Karla PLEVOVÁ, Šárka POSPÍŠILOVÁ, Martin ŠIMKOVIČ, Filip VRBACKÝ, Daniel LYSÁK, Stacey M. FERNANDEZ, MS. DAVIDS, Alba MAIQUES-DIAZ, Stella CHARALAMPOPOULOU, Jose I. MARTIN-SUBERO, Jennifer R. BROWN, Michael DOUBEK, Francesco FORCONI, Jiří MAYER and Marek MRÁZ. FOXO1-RICTOR AXIS induces adaptive increase in AKT activity during BCR inhibitor therapy in CLL: Implications for combination therapy. In \textit{EHA 2023 in HemaSphere (2023)}. 2023. ISSN~2572-9241.
|
